全文获取类型
收费全文 | 329篇 |
免费 | 28篇 |
国内免费 | 23篇 |
专业分类
儿科学 | 18篇 |
妇产科学 | 6篇 |
基础医学 | 35篇 |
口腔科学 | 9篇 |
临床医学 | 38篇 |
内科学 | 91篇 |
皮肤病学 | 30篇 |
神经病学 | 9篇 |
特种医学 | 68篇 |
外科学 | 9篇 |
综合类 | 17篇 |
预防医学 | 4篇 |
药学 | 30篇 |
肿瘤学 | 16篇 |
出版年
2023年 | 2篇 |
2021年 | 2篇 |
2019年 | 5篇 |
2018年 | 5篇 |
2017年 | 3篇 |
2016年 | 2篇 |
2015年 | 11篇 |
2014年 | 5篇 |
2013年 | 11篇 |
2012年 | 4篇 |
2011年 | 4篇 |
2010年 | 11篇 |
2009年 | 17篇 |
2008年 | 11篇 |
2007年 | 20篇 |
2006年 | 11篇 |
2005年 | 9篇 |
2004年 | 6篇 |
2003年 | 9篇 |
2002年 | 6篇 |
2001年 | 6篇 |
2000年 | 1篇 |
1999年 | 7篇 |
1998年 | 21篇 |
1997年 | 15篇 |
1996年 | 28篇 |
1995年 | 8篇 |
1994年 | 18篇 |
1993年 | 8篇 |
1992年 | 4篇 |
1991年 | 6篇 |
1990年 | 10篇 |
1989年 | 7篇 |
1988年 | 14篇 |
1987年 | 10篇 |
1986年 | 8篇 |
1985年 | 11篇 |
1984年 | 5篇 |
1983年 | 5篇 |
1982年 | 6篇 |
1981年 | 6篇 |
1980年 | 5篇 |
1979年 | 1篇 |
1978年 | 3篇 |
1977年 | 4篇 |
1976年 | 6篇 |
1975年 | 3篇 |
排序方式: 共有380条查询结果,搜索用时 0 毫秒
111.
112.
Connelly RJ; Hayden MS; Scholler JK; Tsu TT; Dupont B; Ledbetter JA; Kanner SB 《International immunology》1998,10(12):1863-1872
The combination of anti-CD2 mAb 9.6 and 9-1, specific for distinct
epitopes, induces proliferation of resting human T cells. The mitogenic
activity of this mAb mixture depends upon accessory cells and the 9-1 mAb
Fc domain. To further study the functional properties of these mAb, their
variable regions were cloned and expressed as monospecific single- chain Fv
(scFv) proteins fused to the human IgG1 Fc domain (scFvIg). A novel
bispecific scFvIg was constructed by cloning the two monospecific scFv
binding sites in tandem, with the 9.6 scFv placed N-terminal to the 9-1
scFvIg. Monospecific scFvIg binding to CD2 was comparable to that of the
corresponding parental mAb, while the bispecific scFvIg exhibited binding
activity similar to that of the 9-1 scFvIg. The combination of 9.6 scFvIg
and 9-1 mAb was mitogenic, whereas mixtures including the 9-1 scFvIg were
non-stimulatory, confirming the unique properties of the 9-1 IgG3 Fc.
Without the IgG3 tail, the bispecific 9.6/9-1 scFvIg was directly mitogenic
and was a more potent mitogen than the mAb mixture, but was accessory cell
dependent. Unlike the combination of mAb, the bispecific reagent did not
directly mobilize calcium in T cells. In comparison to the mAb mixture,
bispecific 9.6/9- 1 scFvIg-mediated stimulation of a mixed lymphocyte
reaction was significantly more resistant to inhibition of the CD28
co-stimulatory pathway by the inhibitor CTLA-4-Ig. These results show that
expression of the 9.6 and 9-1 binding sites together on a bispecific scFvIg
increased the mitogenic properties of the mAb and altered the degree of
accessory cell signals required for T cell activation.
相似文献
113.
114.
115.
Levine AM; Bernstein L; Sullivan-Halley J; Shibata D; Mahterian SB; Nathwani BN 《Blood》1995,86(12):4612-4616
The role of zidovudine and other antiretroviral agents in the pathogenesis of acquired immunodeficiency syndrome (AIDS)-related lymphomas has been somewhat controversial. In an attempt to elucidate the precise role of antiretroviral agents in the subsequent development of AIDS-related lymphoma, we performed a population-based, case-control study of human immunodeficiency virus (HIV)-seropositive patients with intermediate- or high-grade lymphoma in Los Angeles County, California, in which information regarding use of antiretroviral medications was ascertained. Diagnostic biopsy material was reviewed to confirm intermediate-or high-grade lymphoma. A structured interview, conducted with all cases and controls, included information about use of zidovudine and other antiretroviral agents. A total of 112 HIV-infected homosexual/bisexual men with lymphoma were matched to 112 homosexual/bisexual men with asymptomatic HIV infection; 49 of the lymphoma cases were also matched to 49 additional controls with AIDS, as defined by conditions other than lymphoma. Positive histories of zidovudine use were reported by 44 (39%) lymphoma cases, 24 (21%) asymptomatic HIV controls, and 21 (42%) AIDS controls. The average duration of zidovudine use up to 12 months before lymphoma diagnosis was 19.0 +/- 13.0 months (mean +/- SD) for the lymphoma cases, 12.6 +/- 10.5 months for the asymptomatic controls, and 11.0 +/- 7.1 months for the AIDS controls. When comparing the 49 HIV-positive lymphoma cases with their 49 matched AIDS controls, all of whom were diagnosed with AIDS during the same time period, the matched relative odds of lymphoma associated with prior use of zidovudine was 0.43 (95% confidence interval [CI] = 0.17 to 1.12). In comparing all 112 lymphoma cases with 49 AIDS controls, the unmatched relative odds of lymphoma associated with zidovudine use was 0.93 (95% confidence interval = 0.47 to 1.83). One lymphoma case and no AIDS control cases had a history of didanosine use; no lymphoma case or AIDS control cases had taken zalcitabine. We conclude that zidovudine is not associated with an increased risk of development of lymphoma among HIV-infected homosexual or bisexual men. 相似文献
116.
117.
118.
119.
120.